Literature DB >> 9028793

Human keratinocytes constitutively express IL-4 receptor molecules and respond to IL-4 with an increase in B7/BB1 expression.

V Junghans1, T Jung, C Neumann.   

Abstract

In certain pathological conditions, such as atopic dermatitis, interleukin-4 (IL-4) can be detected in the skin. As the role of this cytokine in inflammatory skin lesions is not completely clear, we investigated its biological effects on skin keratinocytes. It was found that freshly isolated as well as cultured keratinocytes obtained from normal individuals express mRNA for the IL-4 receptor (IL-4R) and produce IL-4R protein, as determined by flow cytometry. Moreover, IL-4 induced a proliferative response in keratinocytes after 1 day of culture and enhanced B7/BB1 expression in these cells. B7-2 (CD86) mRNA and protein were neither detected on untreated nor IL-4 treated keratinocytes. In contrast to interferon-gamma (IFN-gamma), IL-4 did not induce ICAM-1 (CD54) or HLA-DR-expression. Keratinocytes which had been treated with IL-4 showed an enhanced ability to stimulate allogeneic T-cell proliferation in the presence of staphylococcus enterotoxin B (SEB), (p < 0.01). Neutralizing anti-B7/BB1 monoclonal antibodies did not block this effect. These results indicate that other molecules than B7/BB-1. HLA-DR or ICAM-1 on IL-4-activated keratinocytes may be involved in T-cell stimulation. In conclusion our results suggest that locally produced IL-4, besides modulating keratinocyte membrane molecules, may enable keratinocytes to interact with skin infiltrating lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9028793     DOI: 10.1111/j.1600-0625.1996.tb00135.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  7 in total

1.  Type 2 helper T-cell cytokines induce morphologic and molecular characteristics of atopic dermatitis in human skin equivalent.

Authors:  Marijke Kamsteeg; Mieke Bergers; Roelie de Boer; Patrick L J M Zeeuwen; Stanleyson V Hato; Joost Schalkwijk; Geuranne S Tjabringa
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Severe papillomavirus infection progressing to metastatic squamous cell carcinoma in bone marrow-transplanted X-linked SCID dogs.

Authors:  Michael H Goldschmidt; Jeffrey S Kennedy; Douglas R Kennedy; Hang Yuan; David E Holt; Margret L Casal; Anne M Traas; Elizabeth A Mauldin; Peter F Moore; Paula S Henthorn; Brian J Hartnett; Kenneth I Weinberg; Richard Schlegel; Peter J Felsburg
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Immortalized N/TERT keratinocytes as an alternative cell source in 3D human epidermal models.

Authors:  Jos P H Smits; Hanna Niehues; Gijs Rikken; Ivonne M J J van Vlijmen-Willems; Guillaume W H J F van de Zande; Patrick L J M Zeeuwen; Joost Schalkwijk; Ellen H van den Bogaard
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

4.  Differential regulation of surface receptor expression, proliferation, and apoptosis in HaCaT cells stimulated with interferon-γ, interleukin-4, tumor necrosis factor-α, or muramyl dipeptide.

Authors:  Emale El Darzi; Samer Bazzi; Sarah Daoud; Karim S Echtay; Georges M Bahr
Journal:  Int J Immunopathol Pharmacol       Date:  2017-04-28       Impact factor: 3.219

Review 5.  Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch.

Authors:  Shirin Kahremany; Lukas Hofmann; Arie Gruzman; Guy Cohen
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

6.  Deletion of Interleukin-4 Receptor Alpha-Responsive Keratinocytes in BALB/c Mice Does Not Alter Susceptibility to Cutaneous Leishmaniasis.

Authors:  Melissa Govender; Ramona Hurdayal; Berenice Martinez-Salazar; Kaya Gqada; Shandre Pillay; Lorna Gcanga; Katiuska Passelli; Natalie E Nieuwenhuizen; Fabienne Tacchini-Cottier; Reto Guler; Frank Brombacher
Journal:  Infect Immun       Date:  2018-11-20       Impact factor: 3.441

7.  Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data.

Authors:  Pavel Kovalenko; Mohamed A Kamal; John D Davis; Nidal Huniti; Christine Xu; Ashish Bansal; Brad Shumel; A Thomas DiCioccio
Journal:  Clin Pharmacol Drug Dev       Date:  2021-06-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.